PCRX (Pacira BioSciences) E10: $0.18 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PCRX Pacira BioSciences Inc PCRX
69 GF Score
Price $24.43
GF Value $29.11
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Pacira BioSciences E10?

Pacira BioSciences PCRX -2.36% 69 E10 is $0.18 as of Jun. 2026. GuruFocus rates PCRX with a GF Score™ of 69/100 and a GF Value™ of $29.11 (Modestly Undervalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Pacira BioSciences's adjusted earnings per share data for the three months ended in Jun. 2026 was $0.120. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.18 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Pacira BioSciences's average E10 Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Pacira BioSciences was 75.30% per year. The lowest was 75.30% per year. And the median was 75.30% per year.

As of today (2026-08-10), Pacira BioSciences's current stock price is $24.43. Pacira BioSciences's E10 for the quarter that ended in Jun. 2026 was $0.18. Pacira BioSciences's Shiller PE Ratio of today is 135.72.

During the past 13 years, the highest Shiller PE Ratio of Pacira BioSciences was 500.88. The lowest was 30.00. And the median was 199.18.


Pacira BioSciences  (NAS:PCRX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Pacira BioSciences's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=24.43/0.18
=135.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Pacira BioSciences was 500.88. The lowest was 30.00. And the median was 199.18.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Pacira BioSciences E10 Related Terms


Pacira BioSciences E10 Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences E10 Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.32 -0.08 0.26 0.10 0.11

Pacira BioSciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.10 0.11 0.14 0.18

PCRX vs ALVO, BIOA, COLL: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Shiller PE Ratio falls into.


PCRX
69GF Score
Pacira BioSciences Inc PCRX
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pacira BioSciences's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.12/333.9520*333.9520
=0.120

Current CPI (Jun. 2026) = 333.9520.

Pacira BioSciences Quarterly Data

per share eps CPI Adj_EPS
201609 -0.590 241.428 -0.816
201612 -0.110 241.432 -0.152
201703 -0.520 243.801 -0.712
201706 -0.490 244.955 -0.668
201709 -0.190 246.819 -0.257
201712 0.110 246.524 0.149
201803 -0.260 249.554 -0.348
201806 0.060 251.989 0.080
201809 -0.020 252.439 -0.026
201812 0.200 251.233 0.266
201903 -0.070 254.202 -0.092
201906 0.060 256.143 0.078
201909 -0.150 256.759 -0.195
201912 -0.120 256.974 -0.156
202003 0.190 258.115 0.246
202006 -0.170 257.797 -0.220
202009 2.940 260.280 3.772
202012 0.320 260.474 0.410
202103 0.230 264.877 0.290
202106 0.420 271.696 0.516
202109 0.390 274.310 0.475
202112 -0.120 278.802 -0.144
202203 0.150 287.504 0.174
202206 0.400 296.311 0.451
202209 -0.020 296.808 -0.023
202212 -0.220 296.797 -0.248
202303 -0.430 301.836 -0.476
202306 0.510 305.109 0.558
202309 0.230 307.789 0.250
202312 0.520 306.746 0.566
202403 0.190 312.332 0.203
202406 0.390 314.175 0.415
202409 -3.110 315.301 -3.294
202412 0.340 315.605 0.360
202503 0.100 319.799 0.104
202506 -0.110 322.561 -0.114
202509 0.120 324.800 0.123
202512 0.040 324.054 0.041
202603 0.070 330.213 0.071
202606 0.120 333.952 0.120

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $0.18 mean?
Pacira BioSciences (PCRX) has a E10 of $0.18 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Pacira BioSciences and its competitors.
Is Pacira BioSciences' E10 too high?
Pacira BioSciences' current E10 is $0.18. Overall, Pacira BioSciences has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' E10 compare to ALVO and BIOA?
Pacira BioSciences' E10 of $0.18 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current E10 is $0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (PCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.11, compared to a current price of $24.43 — trading 16.1% below its estimated fair value. The current E10 is $0.18. Pacira BioSciences' overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Pacira BioSciences (PCRX), the current E10 is $0.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (PCRX) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of $24.43 is trading 16.1% below its estimated GF Value™ of $29.11. GuruFocus considers Pacira BioSciences to be Modestly Undervalued.

Key valuation signals for PCRX:

  • E10: $0.18
  • GF Value™: $29.11 vs. price of $24.43 (16.1% below fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the PCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacira BioSciences Business Description

Other Exchanges 82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
69GF Score

Get the complete analysis for PCRX

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.43
Price
$29.11
GF Value